Human Genome Sciences Announces First Quarter 2008 Financial Results and Key De...( - LymphoStat-B(R) Phase 3 trial BL...)

- LymphoStat-B(R) Phase 3 trial BLISS-52 completes enrollment ahead of

previous fall 2008 projection - - Albuferon(R) Phase 3 trial in genotypes 2 and 3 hepatitis C completes

treatment phase -

- Rights to TRAIL receptor antibodies reacquired -

- GlaxoSmithKline announces plan to advance darapladib to Phase 3

development for the treatment of atherosclerosis -

ROCKVILLE, Md., May 5 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results and key developments for the quarter ended March 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"We have continued to make substantial progress toward the commercialization of our lead products since the beginning of 2008," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "In April, we completed the enrollment of BLISS-52, one of our two Phase 3 trials of LymphoStat-B. We now expect to have our first Phase 3 data for LymphoStat-B available by mid-2009. We have completed the treatment phase in ACHIEVE 2/3, one of our two Phase 3 trials of Albuferon, and are on track to have our first Phase 3 data available for Albuferon late this year. We are also investing strategically in our oncology program, a potential key driver of future growth beyond our late-stage products. In April, we reacquired rights to our TRAIL receptor antibodies and announced plans to begin our third randomized chemotherapy combination trial of HGS-ETR1. In addition, darapladib, a product in the GlaxoSmithKline clinical pipeline to which we have substantial fina
'/>"/>